Assembly Bio receives $35M from Gilead HPI option; 5366 and 1179 Phase 1b data exceed targets

Filed May 7, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~2 min read

Key Changes

• high

  Gilead exercised option to license HPI program (5366 and 1179) for $35M net payment in December 2025; company eligible for up to $330M in milestones plus royalties and can opt in to share 40% of U.S. costs and profits.

  MD&A: Gilead Collaboration verify on EDGAR →
• high

  5366 Phase 1b showed 94% reduction in HSV-2 shedding (weekly dosing) and 1179 showed 98% reduction, both exceeding 80-85% target; both candidates ready for Phase 2 with favorable safety profiles.

  MD&A: Clinical Data verify on EDGAR →
• high

  Cash runway extended to 2028 from mid-2026, with $226.6M in cash and marketable securities as of March 31, 2026, reflecting Gilead payments and August 2025 financing.

  MD&A: Liquidity verify on EDGAR →